Tigermed to reduce capital after cancelling repurchased A shares

Hangzhou Tigermed Consulting announced a capital reduction after cancelling 3,922,520 repurchased A shares. This represents 40% of its total repurchased shares, with a value of 200,046,593.34 yuan. This action will decrease the company's total share capital from 864,948,570 shares to 861,026,050 shares, and its registered capital will similarly decrease from 864,948,570 yuan to 861,026,050 yuan. Creditors have 45 days from the announcement date to declare claims.

The share repurchase program, completed by April 30, 2025, involved buying back 9,806,300 A shares for 500,116,483.34 yuan. The repurchased shares were intended for both equity incentives and capital reduction, with at least 40% allocated for the latter. The repurchases occurred at prices between 48.17 yuan and 62.00 yuan per share.

Concurrently, the company addressed a partial share repurchase and release of pledged shares by a major shareholder, Cao Xiaochun. She repurchased and released 2,600,000 pledged shares, representing 5.07% of her holdings and 0.30% of the company's total share capital. Her remaining pledged shares now total 20,000,000, representing 38.98% of her total holdings.